HEADER RECEPTOR 02-JUN-08 2VV0 TITLE HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN, RESIDUES 202-475; COMPND 5 SYNONYM: PPAR GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: DHA SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VARIANT: ROSETTA; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET30A MODIFIED KEYWDS NUCLEAR RECEPTOR, TRANSCRIPTION REGULATION, ALTERNATIVE SPLICING, KEYWDS 2 LIGAND BINDING DOMAIN, DIABETES MELLITUS, ZINC-FINGER, DNA-BINDING, KEYWDS 3 POLYMORPHISM, TRANSCRIPTION, ZINC, OBESITY, NUCLEUS, RECEPTOR, KEYWDS 4 ACTIVATOR, OXIDISED FATTY ACID, TRANSCRIPTION FACTOR, METAL-BINDING, KEYWDS 5 PHOSPHOPROTEIN, DISEASE MUTATION EXPDTA X-RAY DIFFRACTION AUTHOR T.ITOH,L.FAIRALL,J.W.R.SCHWABE REVDAT 8 13-DEC-23 2VV0 1 REMARK REVDAT 7 08-MAY-19 2VV0 1 REMARK REVDAT 6 06-MAR-19 2VV0 1 REMARK REVDAT 5 06-JUN-12 2VV0 1 SOURCE JRNL REMARK VERSN REVDAT 4 24-NOV-09 2VV0 1 VERSN REVDAT 3 24-FEB-09 2VV0 1 VERSN REVDAT 2 28-OCT-08 2VV0 1 JRNL REMARK REVDAT 1 19-AUG-08 2VV0 0 JRNL AUTH T.ITOH,L.FAIRALL,K.AMIN,Y.INABA,A.SZANTO,B.L.BALINT,L.NAGY, JRNL AUTH 2 K.YAMAMOTO,J.W.R.SCHWABE JRNL TITL STRUCTURAL BASIS FOR THE ACTIVATION OF PPARG BY OXIDISED JRNL TITL 2 FATTY ACIDS JRNL REF NAT.STRUCT.MOL.BIOL. V. 15 924 2008 JRNL REFN ISSN 1545-9993 JRNL PMID 19172745 JRNL DOI 10.1038/NSMB.1474 REMARK 2 REMARK 2 RESOLUTION. 2.55 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.2 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : MLF REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.55 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 35.91 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1640828.790 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 97.3 REMARK 3 NUMBER OF REFLECTIONS : 40468 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.218 REMARK 3 FREE R VALUE : 0.261 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT : 2095 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.55 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.71 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 94.60 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 6174 REMARK 3 BIN R VALUE (WORKING SET) : 0.3010 REMARK 3 BIN FREE R VALUE : 0.3260 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.50 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 356 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.017 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4083 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 48 REMARK 3 SOLVENT ATOMS : 59 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 32.50 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 45.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.36000 REMARK 3 B22 (A**2) : 14.17000 REMARK 3 B33 (A**2) : -12.81000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 4.55000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.32 REMARK 3 ESD FROM SIGMAA (A) : 0.38 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.41 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.45 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.90 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.890 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.350 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.280 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.010 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.080 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.40 REMARK 3 BSOL : 58.65 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : DH.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : DH.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: BULK SOLVENT MODEL USED REMARK 4 REMARK 4 2VV0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 02-JUN-08. REMARK 100 THE DEPOSITION ID IS D_1290036461. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-NOV-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.93 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 40468 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.550 REMARK 200 RESOLUTION RANGE LOW (A) : 57.740 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 16.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.55 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.69 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.40 REMARK 200 R MERGE FOR SHELL (I) : 0.30000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 2I4P REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.50 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.80 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM REMARK 280 TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 REMARK 280 DEGREES CELSIUS, VAPOR DIFFUSION, TEMPERATURE 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.54500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.64000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.54500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.64000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 202 REMARK 465 LYS A 261 REMARK 465 ILE A 262 REMARK 465 LYS A 263 REMARK 465 PHE A 264 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 LEU A 476 REMARK 465 TYR A 477 REMARK 465 GLY B 202 REMARK 465 ALA B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 465 GLU B 207 REMARK 465 THR B 241 REMARK 465 THR B 242 REMARK 465 PHE B 264 REMARK 465 LYS B 265 REMARK 465 HIS B 266 REMARK 465 ILE B 267 REMARK 465 THR B 268 REMARK 465 PRO B 269 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 ASP B 462 REMARK 465 MET B 463 REMARK 465 SER B 464 REMARK 465 LEU B 465 REMARK 465 TYR B 477 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 THR B 461 OG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 238 56.36 -112.84 REMARK 500 LYS A 240 45.95 -68.90 REMARK 500 THR A 241 -179.24 179.81 REMARK 500 THR A 242 -11.49 -143.49 REMARK 500 ASP A 396 32.25 -88.23 REMARK 500 HIS A 425 57.94 -143.61 REMARK 500 LYS A 474 3.77 -67.18 REMARK 500 THR B 238 -88.74 -125.63 REMARK 500 LYS B 244 103.72 -56.99 REMARK 500 ASP B 251 -169.46 -168.45 REMARK 500 ILE B 262 -153.65 -127.71 REMARK 500 LEU B 393 46.60 -79.60 REMARK 500 LEU B 453 3.01 -66.59 REMARK 500 THR B 459 54.70 -153.16 REMARK 500 GLU B 460 -66.60 -140.26 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HXA A 1476 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HXA B 1477 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2FVJ RELATED DB: PDB REMARK 900 A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF PEROXISOMEPROLIFERATOR- REMARK 900 ACTIVATED RECEPTOR-GAMMA ( PPARG) RECRUITSPPARG-COACTIVATOR-1 ALPHA REMARK 900 ( PGC1A) BUT POTENTIATES INSULINSIGNALING IN VITRO REMARK 900 RELATED ID: 1FM9 RELATED DB: PDB REMARK 900 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THEHETERODIMER OF REMARK 900 THE HUMAN RXRALPHA AND PPARGAMMA LIGANDBINDING DOMAINS RESPECTIVELY REMARK 900 BOUND WITH 9-CIS RETINOIC ACIDAND GI262570 AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 2PRG RELATED DB: PDB REMARK 900 LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR REMARK 900 ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 1KNU RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATORACTIVATED REMARK 900 RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETICAGONIST REMARK 900 RELATED ID: 1RDT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHALIGAND REMARK 900 BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER REMARK 900 RELATED ID: 1I7I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMANPPAR-GAMMA REMARK 900 IN COMPLEX WITH THE AGONIST AZ 242 REMARK 900 RELATED ID: 3PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED REMARK 900 RECEPTOR REMARK 900 RELATED ID: 1K74 RELATED DB: PDB REMARK 900 THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THEHETERODIMER OF REMARK 900 THE HUMAN PPARGAMMA AND RXRALPHA LIGANDBINDING DOMAINS RESPECTIVELY REMARK 900 BOUND WITH GW409544 AND 9- CISRETINOIC ACID AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 1FM6 RELATED DB: PDB REMARK 900 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THEHETERODIMER OF REMARK 900 THE HUMAN RXRALPHA AND PPARGAMMA LIGANDBINDING DOMAINS RESPECTIVELY REMARK 900 BOUND WITH 9-CIS RETINOIC ACIDAND ROSIGLITAZONE AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 1ZGY RELATED DB: PDB REMARK 900 STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSIONOF THE REMARK 900 ORPHAN NUCLEAR RECEPTOR LRH -1 BY SHP REMARK 900 RELATED ID: 1PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR REMARK 900 ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 2F4B RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMANPPAR-GAMMA REMARK 900 IN COMPLEX WITH AN AGONIST REMARK 900 RELATED ID: 2VST RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)-HODE REMARK 900 RELATED ID: 2G0H RELATED DB: PDB REMARK 900 STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPARPARTIAL REMARK 900 AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHYAND IN VITRO/ IN REMARK 900 VIVO BIOLOGICAL ACTIVITIES REMARK 900 RELATED ID: 2VSR RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE REMARK 900 RELATED ID: 1WM0 RELATED DB: PDB REMARK 900 PPARGAMMA IN COMPLEX WITH A 2-BABA COMPOUND REMARK 900 RELATED ID: 4PRG RELATED DB: PDB REMARK 900 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL REMARK 900 RELATED ID: 2G0G RELATED DB: PDB REMARK 900 STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPARPARTIAL REMARK 900 AGONISTS: VIRTUAL SCREENING, X-RAY CRYSTALLOGRAPHYAND IN VITRO/ IN REMARK 900 VIVO BIOLOGICAL ACTIVITIES REMARK 900 RELATED ID: 1NYX RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATORACTIVATED REMARK 900 RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST REMARK 900 RELATED ID: 2VV3 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4R8 REMARK 900 RELATED ID: 2VV1 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA REMARK 900 RELATED ID: 2VV2 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA REMARK 900 RELATED ID: 2VV4 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUE NUMBERING CORRESPONDS TO ISOFORM 1 DBREF 2VV0 A 202 203 PDB 2VV0 2VV0 202 203 DBREF 2VV0 A 204 477 UNP P37231 PPARG_HUMAN 202 475 DBREF 2VV0 B 202 203 PDB 2VV0 2VV0 202 203 DBREF 2VV0 B 204 477 UNP P37231 PPARG_HUMAN 202 475 SEQRES 1 A 276 GLY ALA LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 A 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 A 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 A 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 A 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 A 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 A 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 A 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 A 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 A 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 A 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 A 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 A 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 A 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 A 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 A 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 A 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 A 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 A 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 A 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 A 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 A 276 ASP LEU TYR SEQRES 1 B 276 GLY ALA LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 B 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 B 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 B 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 B 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 B 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 B 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 B 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 B 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 B 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 B 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 B 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 B 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 B 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 B 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 B 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 B 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 B 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 B 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 B 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 B 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 B 276 ASP LEU TYR HET HXA A1476 24 HET HXA B1477 24 HETNAM HXA DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID FORMUL 3 HXA 2(C22 H32 O2) FORMUL 5 HOH *59(H2 O) HELIX 1 1 ASN A 205 PHE A 226 1 22 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 MET A 257 1 7 HELIX 4 4 GLU A 276 ILE A 303 1 28 HELIX 5 5 ASP A 310 ALA A 331 1 22 HELIX 6 6 ARG A 350 LYS A 354 1 5 HELIX 7 7 PRO A 359 PHE A 363 5 5 HELIX 8 8 MET A 364 ALA A 376 1 13 HELIX 9 9 ASP A 380 LEU A 393 1 14 HELIX 10 10 ASN A 402 HIS A 425 1 24 HELIX 11 11 GLN A 430 GLU A 460 1 31 HELIX 12 12 HIS A 466 TYR A 473 1 8 HELIX 13 13 SER B 208 PHE B 226 1 19 HELIX 14 14 THR B 229 THR B 238 1 10 HELIX 15 15 ASP B 251 ILE B 262 1 12 HELIX 16 16 GLU B 276 LYS B 301 1 26 HELIX 17 17 GLY B 305 LEU B 309 5 5 HELIX 18 18 ASP B 310 TYR B 320 1 11 HELIX 19 19 GLY B 321 ALA B 331 1 11 HELIX 20 20 ARG B 350 SER B 355 1 6 HELIX 21 21 MET B 364 ASN B 375 1 12 HELIX 22 22 ALA B 376 GLU B 378 5 3 HELIX 23 23 ASP B 380 LEU B 393 1 14 HELIX 24 24 ASN B 402 HIS B 425 1 24 HELIX 25 25 GLN B 430 ILE B 456 1 27 HELIX 26 26 HIS B 466 TYR B 473 1 8 SHEET 1 AA 4 PHE A 247 ILE A 249 0 SHEET 2 AA 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 AA 4 GLY A 338 ILE A 341 -1 O VAL A 339 N MET A 348 SHEET 4 AA 4 MET A 334 ASN A 335 -1 O ASN A 335 N GLY A 338 SHEET 1 BA 4 PHE B 247 ILE B 249 0 SHEET 2 BA 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 BA 4 GLY B 338 ILE B 341 -1 O VAL B 339 N MET B 348 SHEET 4 BA 4 MET B 334 ASN B 335 -1 O ASN B 335 N GLY B 338 CISPEP 1 LYS A 358 PRO A 359 0 0.14 CISPEP 2 LYS B 358 PRO B 359 0 1.72 SITE 1 AC1 10 ARG A 288 SER A 289 HIS A 323 TYR A 327 SITE 2 AC1 10 LEU A 340 ILE A 341 SER A 342 MET A 364 SITE 3 AC1 10 HIS A 449 TYR A 473 SITE 1 AC2 9 ILE B 281 CYS B 285 ARG B 288 ILE B 326 SITE 2 AC2 9 LEU B 330 LEU B 333 ILE B 341 SER B 342 SITE 3 AC2 9 MET B 348 CRYST1 93.090 61.280 118.550 90.00 103.19 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010742 0.000000 0.002518 0.00000 SCALE2 0.000000 0.016319 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008664 0.00000